PUBLISHER: Inkwood Research | PRODUCT CODE: 1268541
PUBLISHER: Inkwood Research | PRODUCT CODE: 1268541
The Europe dry eye disease market is predicted to project a CAGR of 4.79% during the forecast period, 2023-2032. Factors such as the growing awareness regarding dry eye disease, the increasing prevalence of glaucoma, the rising geriatric population, and the surging market consolidation are predominately credited to the region's market growth.
Poland, Spain, France, the United Kingdom, Germany, Belgium, Italy, and Rest of Europe are assessed for the Europe dry eye disease market growth evaluation. Italy harbors an advanced healthcare industry, representing a significant market. Glaucoma, as well as retinal disorders, encompass the largest segments. However, dry eye disease is relatively smaller, with no insurance reimbursement offered for the treatment of the same. The Italian Medicines Agency (Agenzia italiana del farmaco, AIFA) is the public institution in the country overlooking the regulatory activities of pharmaceuticals. Further, dry eye disease is more frequent among women in Italy, increasing with age.
In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) oversees the quality, efficacy, and safety of health products and medicines for veterinary and human use and clinical developments. In addition, according to World Health Organization (WHO) stats, health expenditure raised in the past two decades. Furthermore, the presence of ophthalmic clinics boosts the analyzed market's demands in Belgium.
Whereas in Spain, the increasing healthcare expenditure on pharmaceutical development enables growth opportunities. Besides, approximately 42% of the population will be aged above 60 by 2050.
Leading firms operating in the market are Johnson & Johnson, VISUfarma, Novartis AG, etc.